Royalty Pharma PLC $RPRX Position Increased by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. increased its position in Royalty Pharma by 23.5%, acquiring an additional 147,112 shares during the second quarter, bringing its total to 774,160 shares valued at approximately $27.9 million.
• Multiple institutional investors, including Augustine Asset Management and Fifth Third Bancorp, have also increased their holdings in Royalty Pharma, indicating strong institutional interest with over 54% of the stock currently owned by such investors.
• Royalty Pharma recently announced a quarterly dividend of $0.22 per share, with a yield of 2.4%, demonstrating its commitment to returning value to shareholders.

Robeco Institutional Asset Management B.V. increased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 23.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 774,160 shares of the biopharmaceutical company's stock after acquiring an additional 147,112 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.14% of Royalty Pharma worth $27,893,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Augustine Asset Management Inc. raised its holdings in Royalty Pharma by 4.4% during the second quarter. Augustine Asset Management Inc. now owns 6,722 shares of the biopharmaceutical company's stock valued at $242,000 after buying an additional 283 shares in the last quarter. Applied Finance Capital Management LLC increased its stake in shares of Royalty Pharma by 3.0% in the first quarter. Applied Finance Capital Management LLC now owns 11,265 shares of the biopharmaceutical company's stock worth $351,000 after purchasing an additional 329 shares during the period. Fifth Third Bancorp increased its stake in shares of Royalty Pharma by 19.2% in the second quarter. Fifth Third Bancorp now owns 2,137 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 344 shares during the period. MassMutual Private Wealth & Trust FSB increased its stake in shares of Royalty Pharma by 42.1% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 402 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Royalty Pharma by 17.1% in the second quarter. GAMMA Investing LLC now owns 3,017 shares of the biopharmaceutical company's stock worth $109,000 after purchasing an additional 440 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on RPRX. Wall Street Zen lowered Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Royalty Pharma in a research note on Saturday, September 27th. Morgan Stanley lifted their price objective on Royalty Pharma from $51.00 to $54.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. The Goldman Sachs Group assumed coverage on Royalty Pharma in a research note on Tuesday. They set a "buy" rating and a $42.00 price target on the stock. Finally, Citigroup boosted their price target on Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of "Buy" and a consensus price target of $46.00.

Royalty Pharma Stock Down 1.2%

NASDAQ RPRX opened at $36.07 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.74. The stock's 50 day moving average is $36.28 and its two-hundred day moving average is $34.55. The company has a market capitalization of $21.03 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 2.28 and a beta of 0.60. Royalty Pharma PLC has a 1-year low of $24.05 and a 1-year high of $38.00.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.04. The company had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. Equities analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Friday, August 15th. Royalty Pharma's payout ratio is presently 50.87%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.